

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HAYNES et al

Serial No. 10/664,029

Filed: September 17, 2003

For: IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND H2
PEPTIDE (AS AMENDED)



Confirmation No. 2598

Atty. Ref.: 1579-804

Group: 1648

Examiner: Stucker, J.J.

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 14, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies (as may
be required) of each identified document and a translation or a
concise explanation of each non-English language document (such
as a Search Report) is enclosed herewith. Copies of the listed WO

documents were submitted in parent Application No. 09/960,717,
filed September 24, 2001.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];
and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this
Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith;
and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R.
§1.97(e) that each item of information contained in this Information
Disclosure Statement was first cited in a communication from a foreign
patent office in a counterpart foreign application not more than three
months prior to the filing of this Information Disclosure Statement (each
item contained in this IDS was the first citation of that item by a foreign
patent office in a counterpart foreign application which occurred no more
than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement
was cited in a communication from a foreign patent office in a counterpart
foreign application, and, to the knowledge of the person signing this
Statement, after making reasonable inquiry, no item of information
contained in this Statement was known to any individual designated in 37
CFR §1.56(c) more than three months prior to the filing of this Information
Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this
Information Disclosure Statement and any other fees applicable to this
application to Deposit Account No. 14-1140. An original and one (1) copy of

HAYNES et al
Serial No. 10/664,029
July 14, 2005

this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

